



## ASX ANNOUNCEMENT

### ANAGENICS LIMITED – CORPORATE UPDATE

#### **SYDNEY 13 January 2023: Anagenics Limited (AN1)**

Further to the ASX announcements of 8 July 2022 and 9 December 2022 regarding the establishment of a strategic partnership with major shareholder Hancock & Gore Limited (HNG), the Company has now entered into service agreements with HNG and AN1 Director Phillip Christopher to formalise the services to be provided to AN1. The material terms of the agreements are as follows:

- HNG and Phillip Christopher to assist AN1 with M&A transactions, capital management and ongoing strategic advice
- Compensation for the services will be AN1 options (to be issued subject to shareholder approval) as previously announced. AN1 will provide further details with the approvals required at an EGM expected during February 2023
- Initial 12 month contract term. Both parties may agree in writing to an extension of the term at any time.

Approved for release by the Board of Directors.

#### **Anagenics Limited (ASX: AN1)**

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products. Advangen Pty Ltd is Anagenics' wholly owned subsidiary engaged in the development and sale of proprietary first in class, best in class, clinically validated products for hair, skin and body. For further information, please see [www.anagenics.com](http://www.anagenics.com), [www.evolisproducts.com.au](http://www.evolisproducts.com.au) and <https://www.blccosmetics.com/>

#### **Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Anagenics to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as, amongst other, the availability of resources, regulatory environment, the results of marketing and sales activities and competition.